Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
Medicago
Brian J Ward; Alexander Makarkov; Annie Séguin; Stéphane Pillet; Sonia Trépanier; Jiwanjeet Dhaliwall; Michael D Libman; Timo Vesikari; Nathalie Landry